All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Bispecific Antibodies Gain Ground in Frontline Follicular Lymphoma Management

May 27th 2025

Vivek Patel, MD, discusses the evolving roles of chemoimmunotherapy and bispecific antibodies in the first-line follicular lymphoma setting.

Asciminib Shows Early Activity With Multiple TKIs in Chronic Myeloid Leukemia

May 27th 2025

Asciminib plus nilotinib, imatinib, or dasatinib were effective in patients with CML in chronic or accelerated phase.

New Study Unveils Potential Therapeutic Pathways for Aggressive Pediatric Brain Tumor

May 27th 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

CHMP Recommends EU Approval of Frontline Tislelizumab/Chemo for Metastatic Nasopharyngeal Carcinoma

May 27th 2025

The EMA’s CHMP recommended the EU approval of first-line tislelizumab plus chemotherapy for adults with recurrent or metastatic nasopharyngeal carcinoma.

Eftilagimod Alfa/Radiotherapy/Pembrolizumab Yields Favorable Hyalinization/Fibrosis in Soft Tissue Sarcoma

May 27th 2025

Eftilagimod alfa plus radiotherapy and pembrolizumab improved tumor hyalinization/fibrosis rates vs radiotherapy alone in resectable soft tissue sarcoma.

CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

May 27th 2025

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

Full FDA Approval Underscores the Role of Larotrectinib in NTRK Fusion+ Solid Tumors

May 27th 2025

David S. Hong, MD, discusses the full FDA approval of larotrectinib for NTRK fusion–positive solid tumors.

MZB1 TCR-Like CAR T-Cell Therapy Yields Antitumor Activity in Multiple Myeloma and Waldenström Macroglobulinemia

May 27th 2025

Elena Maroto-Martin, PhD, highlights the mechanism of action and efficacy of MZB1 TCR-like CAR T-cell therapy in multiple myeloma.

Treatment Gaps Persist in Advanced Melanoma as Trials Explore Options Beyond Standard Checkpoint and BRAF/MEK Inhibitors

May 27th 2025

Vincent Ma, MD, emphasizes the need for novel therapies for patients with melanoma who are refractory to or ineligible for standard checkpoint inhibition.

SVR With Pacritinib Is Linked With OS Benefit in Myelofibrosis With Thrombocytopenia

May 26th 2025

SVR10 at week 12 was associated with favorable OS among patients with myelofibrosis and thrombocytopenia treated with pacritinib in the PERSIST-2 trial.

Fox Chase Cancer Center Earns Renewal of Prestigious Core Grant from the National Cancer Institute

May 26th 2025

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment.

Talquetamab/Teclistamab Combo Yields Responses With Increased Infection Incidence in Triple Class–Exposed Myeloma

May 26th 2025

Talquetamab plus teclistamab produced responses with a high rate of infections in relapsed/refractory multiple myeloma.

Zanubrutinib Yields High Response Rates in Japanese Patients With CLL/SLL and Waldenström Macroglobulinemia

May 25th 2025

Zanubrutinib showed high response rates and durable responses among Japanese patients with CLL/SLL and Waldenström macroglobulinemia.

Five Under 5: Top Oncology Videos for the Week of 5/18

May 25th 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Post Hoc Data Show Anemia Benefits, Reduced Transfusion Burden With Momelotinib in Myelofibrosis

May 24th 2025

Momelotinib was associated with anemia benefits and reduced transfusion burden in myelofibrosis in a post hoc analysis of 4 trials.

Alana Welm, PhD, Named Chair of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah

May 23rd 2025

Alana Welm, PhD, is now the chair of the Department of Oncological Sciences in the Spencer Fox Eccles School of Medicine at the University of Utah.

Inavolisib Plus Palbociclib/Fulvestrant Earns Positive CHMP Opinion for PIK3CA-Mutated, ER+/HER2– Advanced Breast Cancer

May 23rd 2025

The EMA’s CHMP has recommended the approval of inavolisib plus palbociclib/fulvestrant in PIK3CA-mutated, ER-positive advanced breast cancer.

CHMP Recommends EU Approval of Obe-Cel for Relapsed/Refractory B-ALL

May 23rd 2025

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL

May 23rd 2025

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.